TAYSHA GENE THERAPIES INC (TSHA) Earnings History & Surprises
NASDAQ:TSHA • US8776191061
4.57 USD
+0.08 (+1.78%)
At close: Mar 6, 2026
4.58 USD
+0.01 (+0.22%)
After Hours: 3/6/2026, 8:00:02 PM
Past quarterly earnings results for TAYSHA GENE THERAPIES INC (TSHA), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Release DateMay 13, 2026
PeriodQ4 / 2025
EPS Estimate-$0.10
Revenue Estimate1.927M
Last Reported
Release DateMar 4, 2026
PeriodQ3 / 2025
EPS Reported-$0.09
EPS Surprise -0.01%
Revenue Surprise -100.00%
Beat Rate
63%
EPS and Revenuebeats vs estimates
Quarterly Earnings Results
EPS & Revenue History (USD)
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.09 | -0.09 | -0.01% | 10.00% | 1.409M | -100.00% | -100.00% | |
| Q2 2025 | -0.09 | -0.08 | -9.04% | - | 1.986M | 1.637M | 21.32% | 78.60% |
| Q1 2025 | -0.08 | -0.09 | 15.26% | 20.00% | 2.302M | 1.51M | 52.45% | -32.51% |
| Q4 2024 | -0.07 | -0.08 | 17.32% | -107.61% | 2.022M | 2.355M | -14.14% | -43.90% |
| Q3 2024 | -0.10 | -0.09 | -5.87% | 23.08% | 1.788M | 1.681M | 6.37% | -62.33% |
| Q2 2024 | -0.09 | -0.17 | 46.41% | 76.32% | 1.112M | 2.717M | -59.07% | -53.57% |
| Q1 2024 | -0.10 | -0.11 | 10.38% | 64.29% | 3.411M | 2.612M | 30.59% | -27.52% |
| Q4 2023 | 0.92 | -0.11 | 919.96% | 370.59% | 3.604M | 2.703M | 33.33% | 44.16% |
| Q3 2023 | -0.13 | -0.18 | 26.20% | 79.69% | 4.746M | 2.141M | 121.67% | - |
| Q2 2023 | -0.38 | -0.32 | -19.75% | 54.76% | 2.395M | 1.9M | 26.05% | - |
| Q1 2023 | -0.28 | -0.36 | 22.48% | 78.63% | 4.706M | 1.02M | 361.37% | - |
| Q4 2022 | -0.34 | -0.34 | -1.25% | 74.24% | 2.5M | 8.345M | -70.04% | - |
| Q3 2022 | -0.64 | -0.83 | 23.17% | 52.59% | - | - | ||
| Q2 2022 | -0.84 | -1.02 | 18.03% | 22.94% | - | - | ||
| Q1 2022 | -1.31 | -1.09 | -20.35% | -50.57% | - | - | ||
| Q4 2021 | -1.32 | -1.28 | -3.12% | -26.92% | - | - | ||
| Q3 2021 | -1.35 | -1.10 | -22.74% | -5.47% | - | - | ||
| Q2 2021 | -1.09 | -0.86 | -27.27% | - | - | - | ||
| Q1 2021 | -0.87 | -0.57 | -51.55% | - | - | - | ||
| Q4 2020 | -1.04 | -0.38 | -171.90% | - | - | - | ||
| Q3 2020 | -1.28 | -0.18 | -617.09% | - | - | - | ||
| Q2 2020 | - | - | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
5.88%
Max EPS beat (4)
17.32%
Min EPS beat (4)
-9.04%
Revenue beat statistics
Revenue beat (4)
2
Average Revenue beat (4)
-10.09%
Max Revenue beat (4)
52.45%
Min Revenue beat (4)
-100.00%
Analysis
In the last 4 quarters, TSHA has beaten EPS estimates in 2 out of 4 releases
TSHA has beaten revenue estimates in 2 out of the last 4 releases
In the last 4 quarters, TSHA has beaten the EPS estimates by 5.9% on average.
In the last 4 quarters, TSHA reported -10.1% below the revenue estimates on average.
TAYSHA GENE THERAPIES INC / TSHA Earnings FAQ
When did TAYSHA GENE THERAPIES INC (TSHA) report earnings last quarter?
TAYSHA GENE THERAPIES INC (TSHA) last reported earnings on 3/4/2026.
Can you provide information on whether TAYSHA GENE THERAPIES INC beat earnings estimates in the last quarter?
TAYSHA GENE THERAPIES INC (TSHA) missed EPS estimates and missed revenue estimates in the most recent quarter.
What percentage of the time does TSHA stock beat earnings estimates?
In the last 4 quarters, TAYSHA GENE THERAPIES INC (TSHA) has beaten EPS estimates in 2 out of 4 releases.